TScan Therapeutics Inc. is the latest Massachusetts biotech to trim its workforce as it funnels cash resources toward its most promising drug programs.

The Waltham biotech is going through a strategic prioritization of its clinical work that will extend its cash runway into the second half of 2027.

Stream NBC10 Boston news for free, 24/7, wherever you are. WATCH HERE

More on this story from Boston Business Journal

See Full Page